Articles | Volume 6, issue 5
https://doi.org/10.5194/jbji-6-131-2021
© Author(s) 2021. This work is distributed under the Creative Commons Attribution 4.0 License.
Case report
| 
01 Apr 2021
Case report |
| 01 Apr 2021
| 01 Apr 2021
Coagulation disorders during treatment with cefazolin and rifampicin: rare but dangerous
Related authors
J. Bone Joint Infect., 7, 81–90, 2022
Related subject area
Subject: Anti-bacterial agents | Topic: Adverse effects
Severe acidosis due to 5-oxoprolinase inhibition by flucloxacillin in a patient with shoulder prosthesis joint infection
J. Bone Joint Infect., 7, 71–74, 2022
Cited articles
Angles, E., Mouton, C., Perino, J., Remy, A., and Ouattara, A.:
Hypoprothrombinemia and severe perioperative haemorrhagic complications in
cardiac surgery patients treated with high-dose cefazolin for infective
endocarditis, Anaesth. Crit. Care Pain Med., 37, 167–170,
https://doi.org/10.1016/j.accpm.2017.07.006, 2018.
Barnes, T., Yan, S., and Kaakeh, Y.: Necrotizing esophagitis and bleeding
associated with cefazolin, Ann. Pharmacother., 48, 1214–1218,
https://doi.org/10.1177/1060028014537038, 2014.
Chung, A. H. and Watson, K.: Cefazolin-induced hypoprothrombinemia, Am. J.
Health Syst. Pharm., 65, 823–826, https://doi.org/10.2146/ajhp070243, 2008.
Dahlbäck, B.: Blood coagulation, Lancet, 355, 1627–1632,
https://doi.org/10.1016/S0140-6736(00)02225-X, 2000.
Gay, E., Barthel, A., Rouzic, N., Henriot, B., Quélennec, B., Lorleac'h,
A., Prades, N., and Schmitt, F.: Cefazolin and coagulation disorders: a case
report, Ann. Biol. Clin. (Paris), 76, 104–106,
https://doi.org/10.1684/abc.2017.1314, 2018.
